Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Director departure
CC transcript

AUXILIUM PHARMACEUTICALS INC (AUXL) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/16/2016 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
03/05/2015 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
02/17/2015 SC 13G/A Palo Alto Investors, LLC reports a 9.6% stake in Auxilium Pharmaceuticals, Inc.
02/17/2015 SC 13G AQR CAPITAL MANAGEMENT LLC reports a 5.1% stake in Auxilium Pharmaceuticals, Inc.
02/17/2015 SC 13G/A PUTNAM INVESTMENTS LLC reports a 1.2% stake in AUXILIUM PHARMACEUTICALS INC
02/12/2015 SC 13G/A Artal International S.C.A. reports a 3.2% stake in AUXILIUM PHARMACEUTICALS, INC.
02/10/2015 SC 13G Pentwater Capital Management LP reports a 7.4% stake in Auxilium Pharmaceuticals Inc.
02/10/2015 SC 13G/A VANGUARD GROUP INC reports a 6.1% stake in Auxilium Pharmaceuticals Inc
02/04/2015 SC 13G/A Flynn James E reports a 0% stake in Auxilium Pharmaceuticals, Inc.
02/04/2015 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
02/03/2015 SC TO-I Form SC TO-I - Tender offer statement by Issuer:
01/30/2015 8-K/A Quarterly results
01/30/2015 SC 13G/A BlackRock Inc. reports a 6.4% stake in AUXILIUM PHARMACEUTICALS INC
01/29/2015 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "Amended and Restated Certificate of Incorporation of Auxilium Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Auxilium Pharmaceuticals, Inc",
"Second Supplemental Indenture, among Auxilium Pharmaceuticals, Inc., Endo International plc and Wells Fargo Bank, National Association, as trustee"
01/27/2015 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AUXILIUM ANNOUNCES RESULTS FROM SPECIAL MEETING OF STOCKHOLDERS Chesterbrook, PA, January 27, 2015 — Auxilium Pharmaceuticals, Inc. , a specialty biopharmaceutical company, announced that it held a special meeting of its stockholders today at 8:30 a.m. ET to approve matters relating to the previously announced proposed merger with Endo International plc. The proposal to adopt the amended and restated agreement and plan of merger was passed by stockholders with approximately 84 percent of outstanding shares voting in favor. Auxilium anticipates that the proposed merger transaction will close on Thursday, January 29, 2015. “As we near the anticipated close of the transaction, I would like to take a moment to thank the Auxilium Board of Directors, the Executive Leadership Team and all of the ..."
01/26/2015 SC 13G/A Invesco Ltd. reports a 2.6% stake in Auxilium Pharmaceuticals Inc.
01/20/2015 8-K Other Events
01/20/2015 425 Form 425 - Prospectuses and communications, business combinations
01/16/2015 425 Form 425 - Prospectuses and communications, business combinations
01/16/2015 8-K Other Events
01/16/2015 425 Form 425 - Prospectuses and communications, business combinations
01/09/2015 425 Form 425 - Prospectuses and communications, business combinations
01/09/2015 425 Form 425 - Prospectuses and communications, business combinations
12/24/2014 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
12/22/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease Swedish Orphan Biovitrum AB and partner Auxilium Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xiapex® for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. The use of Xiapex in men with Peyronie's disease is supported by positive safety and efficacy outcome data from two double-blind placebo-controlled studies IMPRESS I and II . In December 2013, the United States Food and Drug Administration approved Xiaflex® for the treatment of adult men with Peyronie's disease with a palpable pl..."
12/19/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/19/2014 425 Form 425 - Prospectuses and communications, business combinations
12/16/2014 425 Form 425 - Prospectuses and communications, business combinations
12/16/2014 425 Form 425 - Prospectuses and communications, business combinations
12/16/2014 425 Form 425 - Prospectuses and communications, business combinations
12/16/2014 8-K Other Events
12/11/2014 425 Form 425 - Prospectuses and communications, business combinations
12/11/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Auxilium Announces Date for Special Meeting of Stockholders"
12/11/2014 425 Form 425 - Prospectuses and communications, business combinations
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy